Add Row
Add Element
cropper
update
[Company Name]
Concierge Health Hub logo
update
Add Element
  • Home
  • Categories
    • Practice Mastery
    • Patient Connect
    • Financial Fitness
    • Tech Advantage
    • Marketing Mastery
    • Regulatory Radar
    • Wellness Wisdom
  • Featured Practices
January 19.2025
2 Minutes Read

The Future of Glaucoma Treatment: Discover iDose TR's Lasting Impact

The Future of Glaucoma Treatment: Discover iDose TR's Lasting Impact


Exciting Development in Glaucoma Treatment

The world of ophthalmology has recently experienced a promising breakthrough with the introduction of the iDose TR, an innovative intracameral implant designed to treat patients with glaucoma. As the demand for effective treatment options grows, this device now shows sustained intraocular pressure (IOP) reductions for up to 36 months. Over 70% of patients who received the implant managed to maintain well-controlled IOP while requiring the same or fewer topical medications compared to only 58% of those treated with timolol, a traditional medication.

How Does iDose TR Work?

iDose TR utilizes a unique delivery system, providing a consistent release of medication directly into the eye. This method minimizes the need for patients to remember daily eye drops, allowing them to adhere better to their treatment regimens. This can be especially beneficial for those who struggle with compliance or have busy lifestyles—two common themes among concierge medical practice clientele.

A Similar Success Story

A related phase 4 study revealed even greater success when combining iDose TR with cataract surgery, achieving a remarkable mean IOP reduction of 11.3 mm Hg at six months. This combination therapy not only highlights the versatility of the implant but also underscores its potential to enhance overall patient satisfaction—a key outcome for concierge practices aiming to deepen patient relationships.

The Future of Glaucoma Management

Excitingly, Glaukos is progressing with a phase 2b/3 clinical program for the iDose TREX, which boasts nearly double the drug capacity of its predecessor. This advancement could further solidify the role of such devices in glaucoma management. For concierge medical practice owners, being aware of these developments might present both an opportunity and a responsibility to educate their patients about innovative treatment options.

Why Concierge Practices Should Prioritize Patient Education

In today’s fast-paced world, keeping patients informed about the latest in medical advancements is crucial. Concierge practices can differentiate themselves by actively discussing options like the iDose TR during consultations. This engagement not only demonstrates a commitment to comprehensive care but also fosters trust and strengthens the patient-practice relationship.

Concluding Thoughts

As healthcare continues to evolve, staying informed and adopting innovative treatments can create a competitive edge for concierge medical practices. Understanding and leveraging breakthroughs like the iDose TR could be a game-changing strategy for practice owners seeking to provide exceptional care and secure their positions as leaders in their communities.


Patient Connect

Write A Comment

*
*
Related Posts All Posts
09.19.2025

Milestone US Vaccine Meeting: Impacts of New Immunization Policies

Discover the potential impacts of US vaccine policy changes on immunization recommendations and public health risks.

09.19.2025

Uninsured Patients Less Likely to Get Vital Interhospital Transfers

Explore how uninsured patients face reduced interhospital transfer odds and what concierge practices can do to enhance patient care.

09.18.2025

How Brain-Health Supplements Can Elevate Patient Care in Concierge Medicine

Explore how brain-health supplements can boost cognitive performance when aligned with nutrition and lifestyle, enhancing patient care in concierge practices.

Terms of Service

Privacy Policy

Core Modal Title

Sorry, no results found

You Might Find These Articles Interesting

T
Please Check Your Email
We Will Be Following Up Shortly
*
*
*